A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. (Q50574814)

From Wikidata

Jump to navigation Jump to search

scientific article published in December 2006

Language	Label	Description	Also known as
English	A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.	scientific article published in December 2006

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

author name string

Ming-Lung Yu

1

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Chia-Yen Dai

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Li-Po Lee

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Nei-Jen Hou

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Ming-Yen Hsieh

5

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Zu-Yau Lin

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Shinn-Cherng Chen

8

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Ming-Yuh Hsieh

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Liang-Yen Wang

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Wen-Yu Chang

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Wan-Long Chuang

12

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

publication date

1 December 2006

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

Liver International

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

26

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

1187-1195

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Therapy of hepatitis C: patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Treatment of hepatitis C patients with normal aminotransferases levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Outcomes of interferon and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Updated definitions of healthy ranges for serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Treatment of patients with hepatitis C and normal serum aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Optimal therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01358A.X

21 January 2018

Identifiers

10.1111/J.1478-3231.2006.01358A.X

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17105583

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50574814&oldid=1540619675"